![Henrik Luer Lueßen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henrik Luer Lueßen
Direttore/Membro del Consiglio presso Alvotech Germany GmbH
Provenienza dei contatti di primo grado di Henrik Luer Lueßen
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Alvotech Germany GmbH
![]() Alvotech Germany GmbH BiotechnologyHealth Technology Baliopharm GmbH operates as biotechnology company. It develops a novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer. The company was founded in 2011 and is headquartered in Juelich, Germany.
1
| Subsidiary | Biotechnology | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Henrik Luer Lueßen tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
3Z ehf
![]() 3Z ehf Investment ManagersFinance 3Z ehf engages in the provision of pharmaceuticals services. Its services include epilepsy, sleep, tailor made screening, acute toxicity, cardiovascular, and neurotox assays. The company was founded in by Karl Karlsson and Haraldur Þorsteinsson in 2008 and Is headquartered in Reykjavík, Iceland. | Investment Managers | Director/Board Member | |
Baliopharm AG
![]() Baliopharm AG Miscellaneous Commercial ServicesCommercial Services Baliopharm AG operates as a biotechnology company. It develops a novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, psoriasis and multiple sclerosis and for cancer. The company was founded in 2011 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Chief Executive Officer | |
SYNIMMUNE GmbH
![]() SYNIMMUNE GmbH Miscellaneous Commercial ServicesCommercial Services Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million. | Miscellaneous Commercial Services | Founder |
Statistiche
Distribuzione geografica
Islanda | 2 |
Svizzera | 2 |
Germania | 2 |
Settori
Commercial Services | 3 |
Finance | 2 |
Posizioni
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Founder | 1 |
Contatti più connessi
Insiders | |
---|---|
Andreas Herrmann | 4 |
- Borsa valori
- Insiders
- Henrik Luer Lueßen
- Connessioni Società